August 23, 2016 — Technavio analysts forecast the global renal denervation market to grow at a compound annual growth rate (CAGR) of close to 12 percent during the forecast period, according to their latest report.
The research study covers the present scenario and growth prospects of the global renal denervation market for 2016-2020. The demand for these devices is high. However, the market is growing slowly as clinical trials have failed to prove the safety and efficacy of many renal denervation devices. Technavio said the market will grow with the U.S. Food and Drug Administration (FDA) approval of Medtronic's SYMPLICITY HTN-4 renal denervation device after the completion of associated clinical study in February 2017.
Europe accounted for more than 57 percent of the market in 2015 due to the CE mark approval of a few of its renal denervation devices.
Technavio healthcare and life sciences analysts highlight the following three factors that are contributing to the growth of the global renal denervation market:
- Widespread prevalence of hypertension;
- Use of minimally-invasive procedures; and
- Technological innovations to simplify renal denervation.
Widespread prevalence of hypertension
According to Barath Palada, a lead analyst at Technavio for medical devices research, “Unhealthy diet, stress and physical inactivity can lead to conditions such as hypertension, hypercholesterolemia, coronary artery disease and diabetes.”
Hypertension or high blood pressure can cause ischemia and stroke. With each passing year, the prevalence of hypertension is rising worldwide. In 2013, the Centers for Disease Control and Prevention (CDC) estimated that more than 30 percent of the global adult population had hypertension. Furthermore, in 2013, the organization estimated that 70 million adults in the United States had high blood pressure, accounting for one in every three adults in the country).
In 2015, the National Health Service estimated that about 500,000 people in the United Kingdom had drug-resistant hypertension. In many cases, blood pressures were higher than 140/90 mmHg and could not be managed even with three or more anti-hypertensives. These cases require the use of renal denervation devices to manage hypertension.
Use of minimally-invasive procedures
Physicians worldwide are emphasizing the use of minimally-invasive techniques in surgical procedures. A rise in the use of minimally-invasive, catheter-based endovascular procedure for managing hypertension has led to higher adoption of renal denervation devices. These devices are safe and effective, and reduce cardiometabolic risks. They also help reduce the length of hospital stays, as the procedure can be completed in about an hour, and people undergoing the procedure only need to stay in the hospital for six more hours or so. This reduces direct and indirect hospitalization costs.
Advances in the procedure have led to the development of a radiofrequency catheter-based approach for renal denervation. Radiofrequency therapy is applied to the endoluminal surface of renal arteries via an electrode located at the tip of the catheter. This type of renal denervation procedure causes no trauma and minimizes recovery time.
Technological innovations to simplify renal denervation
“Manufacturers are developing new catheter-based devices to simplify the technicality and shorten the duration of renal denervation procedures, which augurs well for the growth of the market,” said Barath.
- St. Jude Medical's EnligHTN multi-electrode renal denervation system uses a basket catheter that contains four electrodes, one in each strut of the basket. These struts expand to establish contact between the electrodes and vessel walls. Each electrode activates separately for 90 seconds. The catheter is retrieved and rotated 45 degrees and a second set of ablations are made. Advances in technology have led to the development of intuitive touch-screen generators that reduce the duration of procedures. The device's features allow for simultaneous ablations, which reduces total ablation time from 24 minutes to four minutes.
- Kona Medical’s Surround Sound Renal Denervation System delivers ablation energy to the posterior portion of a patient's body, which eliminates the need for catheterization. The device delivers ultrasound energy, which surrounds the artery and ablates the nerves located in the vicinity of the vessel.
Other vendor offerings include the Vessix renal denervation system from Boston Scientific Corp. and a percutaneous renal denervation system from ReCor Medical Inc.
For more information: www.technavio.com